KALA BIO Stock (NASDAQ:KALA)

Forecast Ownership Financials Chart

Previous Close

$2.47

52W Range

$2.03 - $1.03K

50D Avg

$5.24

200D Avg

$110.81

Market Cap

$57.68M

Avg Vol (3M)

$82.45K

Beta

-2.41

Div Yield

KALA Company Profile

Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Jul 20, 2017

Website

KALA Performance

KALA Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	-	-
Operating Income	$-39.16M	$-40.98M	$-39.15M
Net Income	$-26.98M	$-38.51M	$-42.20M
EBITDA	$-39.16M	$-40.98M	$-36.08M
Basic EPS	$-3.31	$-6.98	$-17.35
Diluted EPS	$-3.31	$-6.98	$-17.35

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q2 22Aug 12, 22 | 8:00 AM

Q1 22May 16, 22 | 8:00 AM

Q4 21Mar 29, 22 | 8:00 AM

Peer Comparison

Ticker	Company
XTLB	XTL Biopharmaceuticals Ltd.
SNGX	Soligenix, Inc.
ABP	Abpro Corporation
ENSC	Ensysce Biosciences, Inc.
VYNE	VYNE Therapeutics Inc.
KTTA	Pasithea Therapeutics Corp.